CASIS, in collaboration with CHU Dijon, the University of Burgundy and Ennoia, a Biotech from Besançon, is developing digital twin technology for patients with chronic aortic dissection.
Although relatively rare, aortic dissection—especially type A—remains a life-threatening condition with high mortality rates.
Through ADEPT, we combine 4D Flow MRI, numerical simulations, histological and blood biomarkers into an AI-driven personalized treatment model.
💡 This approach will enable early identification of high-risk patients, guide optimal intervention timing, and even support surgical training and preoperative planning.
Beyond patient care, ADEPT will also help reduce unnecessary examinations, improve quality of life, and optimize the use of healthcare resources.
Recent Comments